Third U.S. patent on Teva's MS drug Copaxone invalidated
NEW YORK (Reuters) - U.S. patent officials on Thursday invalidated a third patent covering Teva Pharmaceutical Industries' $4 billion multiple sclerosis treatment Copaxone, after cancelling two other patents on the drug last week.
The ruling came in a challenge at the U.S. Patent and Trademark Office by Mylan NV, which is trying to bring out a generic version of the 40-milligram injectable drug, taken three times a week. According to the U.S. Food and Drug Administration, Copaxone is protected by five patents in total.
(Reporting by Andrew Chung; Editing by Alexia Garamfalvi and Leslie Adler)
© Copyright Reuters Ltd. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Reuters Ltd.
